Pilot Study Evaluating Safety and Efficacy of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in OAB Patients
Phase of Trial: Phase I/II
Latest Information Update: 04 Mar 2016
Price : $35 *
At a glance
- Drugs Botulinum toxin (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Therapeutic Use
- Sponsors UroGen Pharma
- 31 Aug 2018 Biomarkers information updated
- 29 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 31 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2015, according to ClinicalTrials.gov record.